AIHA - Warm Autoimmune Hemolytic Anemia study: OM336
Official title OM336 in Autoimmune Cytopenias
ClinicalTrials.gov ID: NCT07083960
What this study is testing
What is OM336?
OM336 is an investigational injectable medicine being studied as a potential treatment for warm autoimmune hemolytic anemia. It is designed to bind both BCMA and CD3, linking immune cells to BCMA‑expressing cells to modulate the immune response.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to learn whether OM336 is safe, how well people tolerate it, and how the drug behaves in the body.
- Who it's for
- Adults who have warm or cold autoimmune hemolytic anemia or immune thrombocytopenia.
- What's involved
- Participants will receive OM336 by a subcutaneous (under‑the‑skin) injection and undergo safety checks and blood tests.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Active autoimmune cytopenia
- Relapsed/refractory after ≥1 prior treatment
- Body weight ≥ 55 kg
- Willing to comply with and study requirements and procedures Key
You likely can't join if
- Previous treatment with a BCMA-targeted therapy
- Clinically significant infection within 3 months of screening
- Major surgery or splenectomy within 3 months of screening or planned during the study
- Pregnant or breastfeeding
The study team makes the final eligibility decision.
Where it is enrolling
- Duarte, California, United States
- Washington D.C., District of Columbia, United States
- Ann Arbor, Michigan, United States
- Seattle, Washington, United States
- Canberra, Australian Capital Territory, Australia
- Sydney, New South Wales, Australia
- Brisbane, Queensland, Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Duarte, California, United States; Washington D.C., District of Columbia, United States; Ann Arbor, Michigan, United States; Seattle, Washington, United States; Canberra, Australian Capital Territory, Australia; Sydney, New South Wales, Australia and 1 more location. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.